Floatz logo

Kyn-5356

Cognitive Dysfunction

Kynexis B.V.Phase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

149 Active assets in the Cognitive Dysfunction cohort.

Asset / SponsorPhaseRating
Ginkgo Biloba Extract
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 4BBB
Rivastigmine
Singapore General Hospital
Phase 4BBB
Nicotine
University of Southern California
Phase 2BBB
Oxybutynin
University of Alberta
Phase 4BBB
Metformin
Fudan University
Phase 4BB

View all 50 →

Same molecule, other indications

Kyn-5356 is also rated in:

schizophreniaDormant
B
Indicative ·
60 / 100
View asset →
schizophreniaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →